Growth dynamics and cyclin expression in cutaneous T-cell lymphoma cell lines

Edyta Biskup,1 Valentina Manfé,1 Maria R. Kamstrup,1 Robert Gniadecki1,2
1Department of Dermatology, Bispebjerg Hospital, Copenhagen; 2Faculty of Health Sciences, University of Copenhagen, Denmark

Abstract

We have investigated cell growth dynamics and cyclins B1 and E expression in cell lines derived from mycosis fungoides (MyLa), Sézary syndrome (SeAx), and CD30+ lymphoproliferative diseases (Mac1, Mac2a, JK). Mac1 and Mac2a had the highest growth rate (doubling time 18-28 h, >90% cycling cells) whereas SeAx was proliferating slowly (doubling time 55 h, approximately 35% cycling cells). Expression of cyclin B1 correlated positively with doubling time whereas expression of cyclin E was unscrambled and constant across the investigated cell lines. All cell lines exhibited high expression of PCNA. Thus, we concluded that cyclin B1 could be used for rapid screening of cell proliferation in malignant lymphocytes derived from cutaneous T-cell lymphoma.

Introduction

Cutaneous T-cell lymphomas (CTCLs) belong to the extra-nodal lymphomas arising primarily in the skin.1 Common types of CTCLs (mycosis fungoides, Sézary's syndrome, and CD30+ lymphoproliferative diseases) are low-grade neoplasms presenting a chronic, relapsing course. Curative treatments are not available, but CTCLs are responsive to ionizing radiation and PUVA (psoralen ultraviolet A therapy) in the early stages. Development of new therapies for the advanced disease is hampered by a lack of suitable animal models, and cell lines have been used for the screening of new compounds. The most commonly used cell lines have been MyLa, SeAx, and Mac1, Mac2a, and JK derived from mycosis fungoides and Sézary syndrome, respectively, and Mac1, Mac2a, and JK are the key regulators of proliferation via activation of the cyclin-dependent kinases. Cyclin expression takes place at specific and well-defined points of the cell cycle; however, in cancer cells unscheduled cyclin expression may be observed.7

Results and Discussion

The proliferation rate of neoplastic cells often reflects their degree of malignancy. In this study we analyzed the growth dynamics of five CTCL cell lines and the expression pattern of cell cycle regulators.

The time required for cell population doubling differed significantly between cell lines tested (Figure 1), with Mac1 and Mac2a being the fastest growing cells (doubling time between 20 and 35 h) and SeAx showing the slowest growth (between 40 and 80 h). These observations were confirmed by BrdU incorporation analysis. After a 20-min pulse with 10 µM BrdU, we observed >90% BrdU positive cells in the case of Mac1, Mac2a, and JK whereas only 40% in the case of MyLa and SeAx cell lines (Figure 1).

Cyclin B1 is an essential G2 cyclin necessary for CDK1 activation and cell entrance into the M phase. Its accumulation begins in the late S phase, reaches the maximal level as the cell enters mitosis, and is degraded rapidly at the beginning of anaphase. An altered expression pattern was observed in several neoplastic cell lines. For example, cyclin B1 has been detected in the G1 phase in HL-60 (leukemic), HS578T, and T-47D (derived from breast carcinoma) cells.8 We did not observe this phenomenon in any of the cell lines we tested. The

Correspondence: Robert Gniadecki, Department of Dermatology D, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark
E-mail: RGNII0001@bbh.regionh.dk
Key words: cutaneous lymphomas, cyclins, proliferation.

Received for publication: 25 March 2010. Accepted for publication: 31 March 2010.
This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0).

©Copyright E. Biskup et al., 2010 License PAGEPress, Italy
Dermatology Reports 2010; 2:e8 doi:10.4081/dr.2010.e8

Figure 1. Growth dynamics of cutaneous T-cell lymphoma cell lines. (A) Measurement of cell doubling time. Cells were seeded in the culture flasks at a density 2×10^5/mL. Mac1, Mac2a and JK cells were grown in RPMI 1640 medium supplemented with 10% FCS; MyLa and SeAx cells were grown in GlutaMAX Dulbecco modified essential medium (DMEM) supplemented with 1 mL L-glutamine and 10% FCS. Media, supplements, and serum were obtained from Gibco BRL. Cell counting was performed twice daily by flow cytometry (Becton-Coulter) until the stationary phase was reached. The time required to double the cell population was calculated using GraphPad Prism (GraphPad Software, San Diego, CA, USA). (B) BrdU incorporation rate. Cells were pulsed for 20 min with 10 µM BrdU, fixed in ice-cold 70% ethanol for at least 20 hr, washed with PBS, and incubated in 2 µM HCl for 30 min prior to the addition of anti-BrdU mouse antibodies (Becton Dickinson). Goat anti-mouse antibodies labeled with Alexa-Fluor 488 (1:1000; Invitrogen) were applied as secondary antibodies. DNA was stained with 7-amino-actinomycin D (7AAP; Beckman Coulter). The percentage of BrdU positive cells was determined by flow cytometry analysis. BrdU incorporation rate (FL1) was plotted versus cellular DNA content (FL3). Quantification of flow cytometry data is provided in (C).

| Cells per cell cycle phase (%) | Mac1 | Mac2a | JK | MyLa | SeAx |
|-------------------------------|------|-------|----|------|------|
| G0/G1*                        | 59.2±7.7* | 56.9±7.6 | 62.1±9.6 | 54.8±13.3 | 71.9±5.5 |
| G2M                           | 14.4±4.0 | 15.1±4.1 | 15.8±4.3 | 20.3±7.0 | 14.1±5.2 |
| S                             | 26.5±4.3 | 28.1±5.3 | 24.2±4.5 | 25.8±7.4 | 13.8±2.7 |

| Proliferation rate | Doubling time (hr) | BrdU incorporation (%) |
|--------------------|--------------------|-------------------------|
| Mac1               | 24.2               | 99.1±10.6 |
| Mac2a              | 26.5               | 99.3±0.5 |
| JK                 | 25.8               | 99.6±1.0 |
| MyLa               | 33.9               | 34.6±4.0 |
| SeAx               | 42.1               | 34.6±4.0 |

*mean with standard deviation
**mean with 95% confidence intervals

[ Dermatology Reports 2010; 2:e8 ] [ page 21 ]
cyclin B1 expression was perfectly scheduled, although the expression level differed among the cell lines tested and tended to be highest in the most rapidly proliferating cells (Figure 2). In contrast, the cyclin E pattern was similar in all cell lines. This factor is essential for cell entrance into the S phase, and therefore it is predominantly expressed in the G1 phase and decreases in the S and G2/M phases. However, we observed that a proportion of S and G2/M cells remained cyclin E positive (Figure 2). This phenomenon represents unscheduled cyclin E expression and has been described before in leukemic cell lines, namely Jurkat, K562, and U937.8

PCNA, a subunit of DNA polymerase α, is a marker for growing cells. Its content increases in the late G1, peaks in the S, and decreases in the G2/M phase.9 In the case of all CTCL cell lines tested, > 90% of cells were PCNA positive, regardless of the growth rate of the cells. We concluded that the cyclin B1 expression is normal in CTCL cell lines and the level of expression roughly correlated with growth rate. In contrast, cyclin E expression is unscheduled and constant in the cell lines we tested. Furthermore, PCNA is not useful as a marker of proliferation rate.

References

1. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.

2. Kalttøft K, Bischalle S, Dyrberg T, et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992;28A:161-7.

3. Kalttøft K, Bischalle S, Rasmussen HF, et al. A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res 1987;279:293-8.

4. Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin’s disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992;326:1115-22.

5. Schiøiemann WF, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999;94:2854-61.

6. Darzykiewicz Z, Gong J, Juan G, et al. Cytometry of cyclin proteins. Cytometry 1996;25:1-13.

7. Gong J, Ardelt B, Traganos F, et al. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 1994;54:4285-8.

8. Viallard JF, Lacombe F, Dupouy M, et al. Flow cytometry study of human cyclin B1 and cyclin E expression in leukemic cell lines: cell cycle kinetics and cell localization. Exp Cell Res 1999;247:208-19.

9. Kurki P, Vanderlaan M, Dolbeare F, et al. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986;166:209-19.